Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Protalix BioTherapeutics, Inc.AMEX: PLX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 87.8%

Gross margin was 87.8% in Q1 FY2026, up 68.7 pp from a year earlier. On a trailing-twelve-month basis it was 70.0%, up 20.0 pp year over year. Over 3 fiscal years it narrowed by 11.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
87.8%+38.4 pp QoQ
Last fiscal yearDec 2025
47.8%-6.6 pp YoY
LTMMar 2026
70.0%+20.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+68.7 pp——
1 year-6.6 pp——
3 years-11.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
47.8%
Year-over-year change
-6.6pp

Gross Margin vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 gross margin of 70.0% is the lowest of the 3 companies compared; the peer median is 85.4%.
  • Its year-over-year change of +20.0 pp is the highest of 3, against a peer median of -1.6 pp.
  • Over three fiscal years its change of -11.0 pp compares with a peer median of -6.0 pp.
PLX Competitors Peer median
Gross Margin for PLX and competitors
Company Period LTM level YoY 3-year change
PHARPharming Group N.V.LTM Mar 202687.3% -1.7 pp-3.6 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
PLXProtalix BioTherapeutics, Inc.LTM Mar 202670.0% +20.0 pp-11.0 pp
PLYXPolaryx Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding PLX) 85.4%-1.6 pp-6.0 pp

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.